SG11201602446VA - Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof - Google Patents

Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof

Info

Publication number
SG11201602446VA
SG11201602446VA SG11201602446VA SG11201602446VA SG11201602446VA SG 11201602446V A SG11201602446V A SG 11201602446VA SG 11201602446V A SG11201602446V A SG 11201602446VA SG 11201602446V A SG11201602446V A SG 11201602446VA SG 11201602446V A SG11201602446V A SG 11201602446VA
Authority
SG
Singapore
Prior art keywords
preparation
pharmaceutical composition
heterocyclic compound
method therefor
fused heterocyclic
Prior art date
Application number
SG11201602446VA
Other languages
English (en)
Inventor
Zusheng Xu
Yangtong Lou
Original Assignee
Shanghai Yingli Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yingli Pharm Co Ltd filed Critical Shanghai Yingli Pharm Co Ltd
Publication of SG11201602446VA publication Critical patent/SG11201602446VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
SG11201602446VA 2013-10-16 2014-09-19 Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof SG11201602446VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310485200 2013-10-16
PCT/CN2014/086914 WO2015055071A1 (zh) 2013-10-16 2014-09-19 稠合杂环化合物、其制备方法、药物组合物和用途

Publications (1)

Publication Number Publication Date
SG11201602446VA true SG11201602446VA (en) 2016-05-30

Family

ID=52827649

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602446VA SG11201602446VA (en) 2013-10-16 2014-09-19 Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof

Country Status (15)

Country Link
US (1) US9656996B2 (zh)
EP (1) EP3059238B1 (zh)
JP (1) JP6139789B2 (zh)
KR (1) KR101982912B1 (zh)
CN (3) CN106831721B (zh)
AU (1) AU2014336775B2 (zh)
CA (1) CA2926596C (zh)
HK (1) HK1209738A1 (zh)
IL (1) IL245112B (zh)
MX (1) MX2016004964A (zh)
NZ (1) NZ718487A (zh)
RU (1) RU2663999C2 (zh)
SG (1) SG11201602446VA (zh)
TW (1) TWI631115B (zh)
WO (1) WO2015055071A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9656996B2 (en) 2013-10-16 2017-05-23 Shanghai Yingli Pharmaceutical Co., Ltd. Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602825A (zh) * 2016-02-05 2018-09-28 中央研究院 具有抗癌活性的嘌呤化合物
MX2018015707A (es) * 2016-06-16 2019-03-21 Janssen Pharmaceutica Nv Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.
US11130751B2 (en) 2017-03-29 2021-09-28 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
SG11202103118PA (en) * 2018-09-27 2021-04-29 Shanghai Yingli Pharmaceutical Co Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
CA3126738C (en) * 2019-01-16 2022-03-15 Shanghai Yingli Pharmaceutical Co., Ltd Preparation method for morpholinquinazoline compound and midbody thereof
CN111848598A (zh) * 2019-04-26 2020-10-30 健艾仕生物医药有限公司 一种含杂环的化合物、其应用及含其的组合物
CN111943938A (zh) * 2019-05-17 2020-11-17 上海再极医药科技有限公司 一种a2a腺苷受体拮抗剂的合成方法
CN113444073B (zh) * 2020-03-26 2024-01-05 上海璎黎药业有限公司 吗啉基喹唑啉类化合物的晶型ⅲ、其制备方法及应用
WO2022199375A1 (zh) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 一种喹唑啉化合物的药物组合物及其制备方法
CN115120596A (zh) * 2021-03-26 2022-09-30 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用
WO2022228218A1 (zh) * 2021-04-30 2022-11-03 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用
CA3217694A1 (en) * 2021-05-24 2022-12-01 Zusheng XU Nitrogen-containing heterocyclic compound, method for preparing same and use of same
TW202315615A (zh) * 2021-09-01 2023-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Pi3k抑制劑與btk抑制劑在製備治療淋巴瘤的藥物中的用途
WO2024041519A1 (zh) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其药物组合物及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2001083456A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2007501801A (ja) * 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
WO2006060390A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Quinoline tachykinin receptor antagonists
JP5270353B2 (ja) 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
US7846929B2 (en) 2006-04-26 2010-12-07 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
DK2050749T3 (en) * 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
BRPI0719112A2 (pt) 2006-11-20 2013-12-10 Novartis Ag Sais e formas de cristal de 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-di-hidro-imi dazo[4,5-c]quinolin-1-il)-fenil]-propionitrila
WO2008127594A2 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
ES2399774T3 (es) * 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
EP2209786B1 (en) 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
AU2009251291B2 (en) * 2008-05-30 2013-05-02 F. Hoffmann-La Roche Ag Purine PI3K inhibitor compounds and methods of use
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
CA2730271A1 (en) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
US8586582B2 (en) 2008-11-11 2013-11-19 Xcovery Holding Company, Llc PI3K/mTOR kinase inhibitors
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
WO2010114484A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010120994A2 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
EP2445902A2 (en) * 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
US8569296B2 (en) 2009-09-29 2013-10-29 Xcovery Holding Company, Llc PI3K (delta) selective inhibitors
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
CA2786294A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
CA2799764A1 (en) 2010-05-19 2011-11-24 Xcovery Holding Company, Llc. Mtor selective kinase inhibitors
US8293736B2 (en) 2010-07-14 2012-10-23 F. Hoffmann La Roche Ag Purine compounds selective for PI3K P110 delta, and methods of use
RS54286B1 (en) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
TWI617560B (zh) 2010-09-14 2018-03-11 伊塞利克斯公司 PI3Kδ 抑制劑以及其應用和生產方法
EP2619209A1 (en) 2010-09-24 2013-07-31 Gilead Calistoga LLC Atropisomers of pi3k-inhibiting compounds
BR112013007123B1 (pt) * 2010-10-01 2021-11-09 Novartis Ag Forma cristalina do sal de monocloridrato de um composto a, seu uso, e composição farmacêutica
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
US20140163023A1 (en) 2011-04-04 2014-06-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
US20130123255A1 (en) 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
FR2986232B1 (fr) 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
EP2860181B1 (en) * 2012-04-10 2019-02-13 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition and uses thereof
WO2015055071A1 (zh) 2013-10-16 2015-04-23 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9656996B2 (en) 2013-10-16 2017-05-23 Shanghai Yingli Pharmaceutical Co., Ltd. Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof

Also Published As

Publication number Publication date
IL245112A0 (en) 2016-06-30
CN104557872A (zh) 2015-04-29
KR20160062170A (ko) 2016-06-01
CN104557872B (zh) 2017-05-24
CN106831722A (zh) 2017-06-13
US9656996B2 (en) 2017-05-23
EP3059238B1 (en) 2020-05-27
TW201518288A (zh) 2015-05-16
AU2014336775B2 (en) 2018-04-05
CN106831721B (zh) 2019-10-22
RU2016115934A (ru) 2017-11-20
KR101982912B1 (ko) 2019-09-10
IL245112B (en) 2020-10-29
TWI631115B (zh) 2018-08-01
CA2926596A1 (en) 2015-04-23
WO2015055071A1 (zh) 2015-04-23
JP2016533372A (ja) 2016-10-27
EP3059238A4 (en) 2017-04-12
RU2663999C2 (ru) 2018-08-14
EP3059238A1 (en) 2016-08-24
US20160244432A1 (en) 2016-08-25
JP6139789B2 (ja) 2017-05-31
HK1209738A1 (zh) 2016-04-08
MX2016004964A (es) 2016-07-11
AU2014336775A1 (en) 2016-04-21
NZ718487A (en) 2020-01-31
CA2926596C (en) 2020-07-14
CN106831721A (zh) 2017-06-13
CN106831722B (zh) 2019-08-30

Similar Documents

Publication Publication Date Title
IL245112B (en) Compressed heterocyclic compound, method for its preparation, pharmaceutical preparation and uses thereof
HK1215567A1 (zh) 五元併六元雜環化合物、其製備方法、藥物組合物和應用
PT2829539T (pt) Novos derivados de pirrole, processo para a sua preparação e composições farmacêuticas que os contenham
IL266301A (en) Antecedents of glutarimide, their use, a pharmaceutical preparation based on them and methods for producing antecedents of glutarimide
EP3053926A4 (en) Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
HK1222563A1 (zh) 藥物組合物、製備及其用途
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
HK1210806A1 (zh) 含免疫細胞組合物的製造方法及癌治療用組合物
HK1213182A1 (zh) 外用藥物組合物
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
IL243227A0 (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
EP2941418A4 (en) N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2952519A4 (en) PROTOPANOXADIOL DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
IL243223A0 (en) History of imidazole, their preparation and pharmaceutical preparations containing them
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
AU2014340351B2 (en) Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
EP2987794A4 (en) VINBLASTINE DERIVATIVES, PROCESS FOR THEIR SYNTHESIS AND THEIR APPLICATION
EP3090736A4 (en) Aqueous composition for hard capsule, and hard capsule produced using same
HK1244814A1 (zh) 一種薯蕷皂苷元-3-位衍生物及其製備方法和用途
EP3090735A4 (en) Aqueous composition for hard capsule, and hard capsule produced using same
IL284405A (en) Pharmaceutical composition, preparation and uses thereof
EP3090734A4 (en) Aqueous composition for hard capsule, and hard capsule produced using same
GB201304625D0 (en) New pharmaceutical composition
ZA201300163B (en) Improved pharmaceutical composition containing an aldosterone antagonist and method for the preparation thereof